We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
-0.68%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$237M
AUM Growth
+$7.37M
Cap. Flow
+$12.7M
Cap. Flow %
5.36%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
EIKN
Eikon Therapeutics
EIKN
+$26M
2
CYTK icon
Cytokinetics
CYTK
+$2.86M

Top Sells

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$16.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
TCM
Tekne Capital Management New York $237M AUM 62.98% 1-Year Est. Return
WW
Windle Wealth Oklahoma City, Oklahoma $237M AUM 22.79% 1-Year Est. Return
CB
CNB Bank Clearfield, Pennsylvania $238M AUM 26.55% 1-Year Est. Return

Foresite Capital Management IV's Q1 2026 Portfolio in Review

As of Q1 2026, Foresite Capital Management IV held 8 positions worth $237M, up 3.2% from $230M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management IV deployed $12.7M of net new capital in Q1 2026, opening 1 new position and adding to 1 existing holding. Its largest new stake was Eikon Therapeutics: 1,943,682 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Maze Therapeutics, an estimated $16.1M trimmed.

  • Foresite Capital Management IV's largest Q1 2026 buy was Eikon Therapeutics: 1,943,682 shares worth $20.6M.
  • Foresite Capital Management IV added most to Cytokinetics in Q1 2026, an estimated $2.86M increase.
  • Foresite Capital Management IV's biggest Q1 2026 reduction was Maze Therapeutics, cutting an estimated $16.1M.
  • Foresite Capital Management IV's ten largest holdings make up 100% of its $237M portfolio in Q1 2026.
  • Foresite Capital Management IV opened 1 new position and closed 0 in Q1 2026.
  • Foresite Capital Management IV's portfolio value rose 3.2% quarter-over-quarter to $237M.

Based on Foresite Capital Management IV's 13F filing for Q1 2026, filed 15 May 2026.